Anal Cancer - A Pipeline Analysis Report

Overview of the drug development pipeline for anal cancer

Anal Cancer is an abnormal malignant cell growth in the tissues of the anus, the distal opening of the gastrointestinal tract. These cell growths are largely caused by human papillomavirus (HPV). Early growth of HPV is sometimes harmless and can be cured if treated on time. While, on the other hand, it can develop into cancer as well. HPV is usually a sexually transmitted virus and is the major cause of anal cancers. The human body constantly makes new cells and helps them to grow. Cancer is developed when the cells do not grow, and divide in their usual way and tend to form a lump called tumor. Anal cancer can be divided into two parts, cancers of the anal canal and cancers of the anal margin. According to the CDC, HPV is responsible for nearly 91% of the anal cancers. HPV is a sexually transmitted infection, and various case-controlled studies have effectively demonstrated that sexual risk factors highly associated with anal cancer.

According to this pipeline analysis report, most of the drug development molecules in the pipeline are being developed for anal cancer. Our market research analysts have also identified that most of these molecules are in the pre-clinical development stage and a considerable number of molecules have been discontinued from development.

Companies covered

This pipeline analysis report provides a detailed analysis of the companies that are involved in the development of drug development molecules for the treatment of anal cancer. In addition to providing information on the various stages of molecules developed by companies for different indications, this pipeline analysis report also provides information about the drug development molecules discontinued by companies.

Some of the companies covered in this pipeline analysis report are –

• BioMimetix Pharmaceutical
• PDS Biotechnology
• ORYX

Therapeutic assessment of the drug development pipeline for anal cancer by route of administration

• Intravenous
• Subcutaneous
• Intravenous+oral
• Subcutaneous+intradermal

The intravenous route of administration (ROA) involves the application of the drug directly onto the vein, which will have a more direct effect on the target cells.

Therapeutic assessment of the drug development pipeline for anal cancer by therapy

• Combination therapy
• Monotherapy
• Monotherapy/combination therapy

According to this pipeline analysis report, all the molecules that are currently in the drug development pipeline for anal cancer are being developed as combination therapy drugs and most of these molecules are in the pre-clinical stage of development.

Key questions answered in the report include

• What are the drug development in the various development stages for anal cancer?
• What are the companies that are currently involved in the drug development for anal cancer?
• Insight into discontinued/inactive molecules with appropriate reasoning?
• What are the major regulatory authorities approving drugs in various regions?
• Detailed profiling of each active molecule

Technavio also offers customization on reports based on specific client requirement.